Merocarb (Meropenem Anhydrous)

Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins located on the bacterial cell wall. This binding blocks the transpeptidation step of peptidoglycan synthesis, preventing cell‑wall cross‑linking. The resulting structural weakness leads to osmotic lysis and bacterial death. Its molecular structure also confers resistance to most β‑lactamases, allowing activity against many resistant pathogens.

The specific dose of Merocarb is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local susceptibility patterns. Dosing regimens are individualized and may range from 0.5 g to 2 g administered intravenously every 8 hours, with adjustments for renal impairment. Exact dosing instructions must be obtained from the treating physician.

Safety data for meropenem in pregnancy and lactation are limited. The drug should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Breastfeeding mothers should consult their healthcare provider, as meropenem can be excreted in breast milk. Decisions are made on a case‑by‑case basis by the prescriber.

To place an order, visit the product page for Merocarb on the GNH India website (gnhindia.com) and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including any cold‑chain requirements—and assistance with import documentation.

Meropenem shares the broad‑spectrum activity of other carbapenems such as imipenem‑cilastatin and ertapenem, but it offers a slightly broader Gram‑negative coverage and greater stability against many β‑lactamases. Compared with non‑carbapenem options like extended‑spectrum cephalosporins, meropenem provides more reliable efficacy against multidrug‑resistant organisms, though it is typically reserved for severe infections due to cost and stewardship considerations.

Merocarb, supplied as a sterile powder for reconstitution, must be stored refrigerated at 2 °C to 8 °C. The product should remain in its original container, protected from light, and must not be frozen or shaken. Once reconstituted, the solution should be used within the time frame specified in the product labeling and kept at room temperature if required for administration.

Merocarb is administered intravenously by slow infusion, typically over 15–30 minutes, using aseptic technique. The reconstituted solution is diluted in an appropriate compatible IV fluid and delivered through a dedicated line or compatible infusion set. Administration rates and duration are determined by the prescribing clinician based on the infection severity and patient-specific factors.

The most serious adverse events linked to meropenem include seizures, especially in patients with renal dysfunction or pre‑existing CNS disorders; severe hypersensitivity reactions such as anaphylaxis; and Clostridioides difficile‑associated colitis, which can lead to life‑threatening diarrhea. Monitoring renal function, neurological status, and signs of allergic reaction is essential during therapy.

Merocarb should be avoided in individuals with a documented hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Patients with uncontrolled epilepsy or a history of seizures may require alternative therapy or close monitoring. Additionally, use is contraindicated in patients with severe renal impairment unless dose adjustments are made under medical supervision.